Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.
about
Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screeningA Review of the External Validity of Clinical Trials with Beta-Blockers in Heart FailureBeta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent dosesModeling the effects of β1-adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca2+ handling.Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy.Medical management of congestive heart failure.Clinical Pharmacology of Carvedilol.Beta-blockers for congestive heart failure: what is the current consensus?Sympathetic activation and the role of beta-blockers in chronic heart failure.beta-blockers in heart failure: recently completed and ongoing clinical trials.Congestive heart failure.Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation.Carvedilol versus other beta-blockers in heart failure.Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure.Beta-blocker treatment in heart failure.Race, sex, and age differences in heart failure-related hospitalizations in a southern state: implications for prevention.β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trialsBeta-blocker benefit according to severity of heart failure.Prediction of the effectiveness of long-term beta blocker treatment for dilated cardiomyopathy by signal averaged electrocardiography.Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study.Beta-blockade in heart failure: selective versus nonselective agents.Outpatient management of congestive heart failureBeta-blockers for congestive heart failure.Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.Interactions between the sympathetic nervous system and the RAAS in heart failure.ACE inhibitors in pediatric patients with heart failure.Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.Beta receptor antagonists in the treatment of heart failure.Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade.Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol.Metoprolol treatment for two years after coronary bypass grafting: effects on exercise capacity and signs of myocardial ischaemiaReductions in muscle sympathetic nerve activity after long-term metoprolol for dilated cardiomyopathy: preliminary observations.Clinical Characteristics and Treatment of Cardiomyopathies in Children.A meta-analysis of the effects of β-adrenergic blockers in chronic heart failureRecent developments in the treatment of congestive heart failure.Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II.β-Blockers in heart failure: benefits of β-blockers according to varying male proportions of study patients.β-Adrenergic blockade in cardiovascular disease.Neurohumoral activation in congestive heart failure: a double-edged sword?The management of heart failure and the scope for new therapies: what role for xamoterol?
P2860
Q26828408-9E94DD6D-7883-471F-8256-FDC4B4D74771Q28068618-1C2292A6-A25E-4483-BC27-95D7330BFF27Q28379279-CB120B79-F6A6-409E-83B3-5E02E16DFD5DQ30371695-E1085178-5C7F-4CFE-BB93-024ACA10D05EQ30539904-7FBED842-406D-41E9-9FD2-38718A9D0C07Q33558612-1CA8828C-360C-4B77-A3D1-F3DB8431C497Q33843419-20CF6231-772A-4AD2-8016-2884416472F9Q33873267-EB975472-D7D1-4816-927C-86827BA47C28Q33951267-8BA3C242-CF08-4DE5-A5BC-9544F8E5DF25Q34074729-7D868E08-068A-49B4-9012-6B7CE41C0A00Q34101370-8E51CB86-79BA-4E78-8777-4E556B0B4074Q34153068-1C4EDFE3-6EE0-4C83-A46D-4BA794B7E46CQ34232069-86E041E0-566E-441F-97D3-6139DF0B2C31Q34264682-FDC0524C-E378-4790-BF05-0D08BCB825F6Q34316468-BA1626A9-CC1D-4509-9E4C-DB9AFE3F5E33Q34760994-88B046E4-3F47-457C-912C-12441B23B3B5Q34815329-07351297-8A42-40E1-9049-9059EBFAFB00Q35150702-DA612698-4D7B-49D2-BC7F-D8BA872054CCQ35366950-BD8BB079-F20D-4F65-B6CC-40F8A004438AQ35582518-2B6D8A10-19AD-43EB-8510-D5446B028C8AQ35631382-60778CB7-888E-4A90-A841-71C6D318A558Q35665407-93FE4B4C-7BF1-4010-8423-2C3DEF75B58FQ35677695-EB956D7B-9CDB-4641-BF4E-9D5B779EFAA2Q35985739-E4FF6FEF-4399-4DCD-83BB-14E180C1E11CQ36203046-DD530875-87CB-4FBE-843B-8CABFB30A192Q36403677-2B4264E3-9810-4028-B3BF-4BCAC30F7DFAQ36421944-2AB07D08-4A48-4328-ADAA-B71E9E2CE876Q36514094-79FDC867-3532-40AA-A6DE-3C2FC0A42805Q36551979-F214661B-0FDF-491A-9DD4-B8F0AE72A582Q36822663-E261CDC9-B7DE-4F6C-BBBF-6DE8ECB74F9BQ36823446-441C098F-DFB4-4C26-8FE4-CA0F7D1CD17DQ36824560-B09B59C9-FCEB-45BB-A4E3-B598399E1E5DQ36886275-0E8B4872-32B0-4241-AD6E-4F05FAB09A18Q37289514-9D1643B9-6152-41C2-8574-7FFAB9ED1177Q37615740-4231E067-226C-4623-9D16-587B36C90FBAQ37827023-FC599BB1-93D2-4C5B-9E6A-0A250E46D42DQ38001302-498BF486-BA79-4924-BBD9-64B1A7A3322EQ38103516-8A0F9D00-1147-40C6-8981-10B49F32750FQ38365094-534680B7-F533-4192-A4A3-87FBEC6B6B5BQ38365789-2ACAFBCF-1053-4C44-AC64-9954FCE3AD28
P2860
Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Improvement in symptoms and ex ...... zed, placebo-controlled trial.
@en
Improvement in symptoms and ex ...... zed, placebo-controlled trial.
@nl
type
label
Improvement in symptoms and ex ...... zed, placebo-controlled trial.
@en
Improvement in symptoms and ex ...... zed, placebo-controlled trial.
@nl
prefLabel
Improvement in symptoms and ex ...... zed, placebo-controlled trial.
@en
Improvement in symptoms and ex ...... zed, placebo-controlled trial.
@nl
P2093
P356
P1433
P1476
Improvement in symptoms and ex ...... zed, placebo-controlled trial.
@en
P2093
P304
P356
10.1161/01.CIR.72.3.536
P407
P577
1985-09-01T00:00:00Z